AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

[1]  M. G. Marciani,et al.  Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia , 2004, Clinical Neurophysiology.

[2]  D. Harvey,et al.  Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia , 2004, Neurology.

[3]  G. Bernardi,et al.  P3-020 Differential diagnosis amongst primary degenerative, mixed and vascular dementia: the contribution of the routine CSF title of Aβ 1–42, T-Tau and P-Tau181 , 2004, Neurobiology of Aging.

[4]  J. C. Torre.  Alzheimer's disease is a vasocognopathy: a new term to describe its nature. , 2004 .

[5]  Henrik Zetterberg,et al.  APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.

[6]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[7]  M. Albert,et al.  Amnestic MCI or prodromal Alzheimer's disease? , 2004, The Lancet Neurology.

[8]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[9]  D. Royall,et al.  A diagnostic dilemma: is “Alzheimer's dementia” Alzheimer's disease, vascular dementia, or both? , 2004, The Lancet Neurology.

[10]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[11]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[12]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[13]  L. Parnetti,et al.  Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice , 2003, Neurological Sciences.

[14]  Nick C Fox,et al.  Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC , 2003, Journal of neurology, neurosurgery, and psychiatry.

[15]  K. Jellinger,et al.  The impact of cerebrovascular lesions in Alzheimer disease , 2003, Journal of Neurology.

[16]  K. Blennow,et al.  CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.

[17]  H. Hampel,et al.  Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein , 2003, Brain Research Bulletin.

[18]  Frederik Barkhof,et al.  Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study , 2003, Stroke.

[19]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[20]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[21]  Lars-Olof Wahlund,et al.  Prognostic significance of white matter changes in a memory clinic population , 2003, Psychiatry Research: Neuroimaging.

[22]  H. Hampel,et al.  Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease , 2003, Neuroscience Letters.

[23]  A. Vagnucci,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Alzheimer's Disease and Angiogenesis , 2022 .

[24]  G. Román,et al.  Defining dementia: clinical criteria for the diagnosis of vascular dementia , 2002, Acta Neurologica Scandinavica, Supplementum.

[25]  K. Blennow,et al.  Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia , 2002, Dementia and Geriatric Cognitive Disorders.

[26]  A. Waldman,et al.  Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. , 2002, Archives of gerontology and geriatrics.

[27]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[28]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[29]  P. Sachdev,et al.  Differentiation of vascular dementia from AD on neuropsychological tests , 1999, Neurology.

[30]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[31]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[32]  H. Arai,et al.  No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia , 1998, Neuroscience Letters.

[33]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[34]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[35]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[36]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[37]  S Ropele,et al.  CT and MRI rating of white matter changes. , 2002, Journal of neural transmission. Supplementum.

[38]  K. Blennow,et al.  Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. , 2000, Journal of Alzheimer's disease : JAD.

[39]  C. Caltagirone,et al.  The Mental Deterioration Battery: Normative Data, Diagnostic Reliability and Qualitative Analyses of Cognitive Impairment , 1996 .

[40]  J. Hanley.  Receiver operating characteristic (ROC) methodology: the state of the art. , 1989, Critical reviews in diagnostic imaging.

[41]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[42]  H. Feldman,et al.  Section Editor: Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment , 2022 .